A decade of trauma and a journey to healing
Fatima Ibrahim (name changed) was just a child when her world was torn apart. At age 10, she was abducted during a violent raid on her village in Bama, Borno State. What followed was a decade of unimaginable hardship and suffering.
Now 20 and a mother of one, Fatima is taking the first steps toward reclaiming her life.
A decade of darkness
Fatima's years in captivity were marked by fear, violence, and profound isolation, enduring both psychological and physical trauma, leaving her scarred. Her eventual release brought relief but also new struggles. In addition to emotional distress, she suffered from a severe gynaecological condition, manifesting as a foul-smelling discharge and vaginal prolapse—complications that significantly impacted her quality of life. With medical care and psychosocial support provided by the World Health Organization (WHO) and other humanitarian health partners, Fatima is gradually finding hope and healing.
'I lost hope many times,' Fatima recalled. 'I thought I would never see my family again or feel safe,' she shared with a trembling voice when speaking to the WHO-supported Hard-to-Reach Mobile Health Team at the Malkohi Internally Displaced Persons (IDP) Camp in Adamawa State, where she had sought refuge.
Referral and the road to healing
Fatima required immediate, specialised medical attention. Recognising the severity of her condition, the WHO health team promptly referred her case to the WHO Gender-Based Violence (GBV) focal person in Yola, initiating a coordinated response among partners and organisations to secure her treatment and rehabilitation.
The International Committee of the Red Cross (ICRC) covered the costs of Fatima's medical treatment. At the same time, the Neems Foundation provided critical assistance, including food and transportation, ensuring she could focus on her recovery without additional burdens. She underwent surgery to address her gynaecological complications and received continuous psychosocial support to aid her emotional recovery.
With funding from the European Union Humanitarian Aid (ECHO), WHO has played a crucial role in delivering essential medical and psychological support to vulnerable populations affected by humanitarian crises. These collaborative efforts ensure that survivors of conflict and gender-based violence, like Fatima, receive comprehensive and tailored care.
By addressing physical and psychological health, WHO and its partners are building pathways for survivors to regain their dignity and access essential health services in challenging environments.
A lifeline of support
In Adamawa State, WHO—supported by the European Commission (ECHO)—has worked alongside the state government to train and deploy seven teams of hard-to-reach healthcare workers, comprising nurses, community health extension workers, and other essential cadres. These teams operate across 17 local government areas, delivering vital healthcare and psychosocial services to vulnerable communities.
Isaac Kadala, a health official in Adamawa State, commended WHO's unwavering commitment to equitable healthcare access, emphasising the organisation's leadership in GBV response and psychosocial training for frontline health workers.'WHO's interventions, including joint supportive supervision across health facilities, have strengthened our capacity to provide much-needed services to affected populations,' he noted, reaffirming the state's commitment to continued collaboration with WHO and its partners.
Sustaining humanitarian action
'WHO's interventions, in this case, and many others, align with our Country Cooperation Strategy IV (CCSIV), which prioritises addressing the health needs of vulnerable populations amid humanitarian crises. By providing comprehensive care, we ensure that no one is left behind in accessing essential health services,' said Dr Kumshida Yakubu Balami, WHO's Acting Emergency Manager for Northeast Nigeria's Humanitarian Health Emergency Response.
Dr Balami emphasised that Fatima's story serves as a critical reminder of the need for sustained investments in survivor-centred healthcare and psychosocial support for victims of gender-based violence.
In 2024 alone, WHO's interventions reached over 161 405 vulnerable individuals in Adamawa State, particularly those residing in IDP camps and remote areas, providing essential medical and psychosocial support.
Fatima's journey illustrates the profound impact of humanitarian health interventions on conflict-affected populations. However, her story also underscores an urgent call for continued global and local commitments to supporting survivors of gender-based violence and investing in comprehensive, accessible healthcare services for the most vulnerable.
Distributed by APO Group on behalf of World Health Organization (WHO) - Nigeria.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Sharjah 24
9 hours ago
- Sharjah 24
WHO warns of rising COVID-19 cases linked to new variant
No increased health risk, but caution urged Although the WHO has confirmed that the new variant does not present a higher health risk compared to earlier strains, it stressed that the virus's continued evolution could trigger new waves of infection in the future. Seasonal pattern and immunity help limit severe cases The organisation noted that the current increase in cases is consistent with the virus's seasonal trends. However, the need for hospitalisation or intensive care remains limited, thanks to strong community immunity and widespread vaccine coverage. WHO calls for vigilance and stronger surveillance Despite the limited severity, the WHO has classified the global risk level as 'high' and called on countries to enhance health surveillance, integrate COVID-19 into seasonal respiratory illness planning, counter misinformation, and encourage the public to follow preventive guidelines.
Gulf Today
9 hours ago
- Gulf Today
WHO warns of rising COVID-19 cases due to new variant
The World Health Organisation (WHO) has warned of a rise in COVID-19 infections linked to the emergence of a new variant, NB.1.8.1, which is currently under investigation. While the organisation confirmed that the new variant does not pose a greater health risk than previous strains, it noted that the continued evolution of the virus could lead to new waves of infection. WHO stated that the current increase aligns with the virus's seasonal pattern and emphasised that the need for hospitalisation or intensive care remains limited due to widespread community immunity and vaccination coverage. The global health body classified the overall global risk level as "high', urging countries to strengthen health surveillance, integrate COVID-19 into seasonal respiratory disease strategies, combat misinformation, and encourage individuals to adhere to preventive measures. WAM
Khaleej Times
11 hours ago
- Khaleej Times
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him. Four days later, he woke up from a coma. "I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin. This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time. From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times. Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home. After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists. But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom. The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom. This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes. Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization. These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas. 'Pain every time' Friede's first bite was from a harmless garter snake when he was five years old. "I was afraid, I cried, I ran away," said Friede, now 57. Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted. Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom. How antivenom is made has changed little over the last 125 years. Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom. However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock. "I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said. He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes. "There is pain every time," he said. 'Proud' For years, the scientists he contacted to take advantage of his immunity refused to bite. Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom. Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites. When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood." "I've been waiting for this call for a long time," came the response, Glanville said. The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib. It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six. The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia. Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies. Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down. Friede said he was "proud" to have made a "small difference" in medical history. Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues. But he hopes to get bitten by snakes again in the future. "I do miss it," he said.
